Class of Warrant or Right [Axis]
Warrant [Member]
Award Type [Axis]
Stock Option Plan [Member]
Options Granted to Consultants [Member]
Exercise Price Range [Axis]
Range One [Member]
Options Granted to Employees [Member]
Related Party [Axis]
Lender Warrants [Member]
Underwriter Warrants [Member]
Range Two [Member]
Range Three [Member]
Range Four [Member]
Range Five [Member]
Warrants Issued to Investor Relations Consultant [Member]
Range [Axis]
Minimum [Member]
Maximum [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Customer Relationships [Member]
Trade Name [Member]
State Pharmacy Licenses [Member]
Non-Competition Clause [Member]
Title of Individual [Axis]
Employees [Member]
Income Statement Location [Axis]
Selling and Marketing [Member]
General and Administrative [Member]
Directors [Member]
Consultants [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
Billing and Collection Agreement [Member]
Third Party [Member]
Restricted Stock Units [Member]
Financial Instrument [Axis]
Loan Agreement [Member]
Life Sciences Alternative Funding LLC [Member]
Patents [Member]
Trademarks [Member]
Plan Name [Axis]
2007 Incentive Stock and Awards Plan [Member]
Agreement [Axis]
Sales Agreement [Member]
Antidilutive Securities [Axis]
Deferred Acquisition Obligations, Stock Options, Unvested RSUs and Warrants [Member]
Note Purchase Agreement [Member]
Debt Instrument [Axis]
8.00% Convertible Senior Secured Note [Member]
Lender [Member]
Liability Class [Axis]
Warrant Derivative Liability [Member]
Embedded Conversion Feature Derivative Liability [Member]
Pharmacy Creations, LLC [Member]
Notes Payable [Member]
Vesting [Axis]
Tranche 1 [Member]
Tranche 2 [Member]
Tranche 3 [Member]
Tranche 4 [Member]
Tranche 5 [Member]
Equity Components [Axis]
Lease Agreement [Member]
Warrant Granted [Member]
Settlement Warrants [Member]
Other [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Business Acquisition [Axis]
Acquisition of Park [Member]
Park [Member]
Restricted Stock [Member]
Sellers [Member]
Other 2015 Acquisitions [Member]
Non-Competition Clause [Member]
Accelerated [Member]
Asset Class [Axis]
Intangible Assets [Member]
Goodwill [Member]
Exchange Agreement [Member]
Placement Agent Warrants [Member]
PIPE Investor Warrants [Member]
Warrant One [Member]
Warrant Two [Member]
Warrant Three [Member]
Underwriting Agreement [Member]
PC [Member]
Non Employee Director [Member]
Mark L. Baum [Member]
Securities Purchase Agreement [Member]
Investor Warrants [Member]
Agent Warrant [Member]
Option Indexed to Issuer's Equity, Type [Axis]
Stock Option One [Member]
Mark Baum [Member]
Baum Performance Option [Member]
Andrew R. Boll [Member]
John P Saharek [Member]
Mr. Boll [Member]
Boll Performance Equity Award [Member]
Mark L Baum [Member]
Unvested RSUs [Member]
Lease Agreements [Member]
License Agreement [Member]
Legal Entity [Axis]
Urigen Pharmaceuticals, Inc [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Imprimis TX [Member]
Livernois [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity Well-known Seasoned Issuer
Entity Voluntary Filer
Entity Current Reporting Status
Entity Filer Category
Entity Public Float
Entity Common Stock, Shares Outstanding
Trading Symbol
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current assets
Cash and cash equivalents
Restricted cash and short-term investments
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Total current assets
Property, plant and equipment, net
Intangible assets, net
Goodwill
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Deferred revenue and customer deposits
Current portion of deferred acquisition obligation and accrued interest
Current portion of contingent acquisition obligation
Current portion of note payable, net of unamortized debt discount
Current portion of capital lease obligations, net of unamortized discount
Total current liabilities
Capital lease obligations, net of current portion and unamortized discount
Deferred acquisition obligation, net of current portion
Accrued expenses, net of current portion
Deferred tax liability
Note payable and paid-in-kind interest, net of unamortized debt discount and current portion
TOTAL LIABILITIES
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, $0.001 par value, 90,000,000 shares authorized, 18,627,915 and 9,755,678 shares issued and outstanding at December 31, 2016 and 2015, respectively
Additional paid-in capital
Accumulated deficit
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Revenues:
Sales, net
License revenues
Total revenues
Cost of sales
Gross profit
Operating expenses:
Selling and marketing
General and administrative
Research and development
Impairment of long-lived assets
Total operating expenses
Loss from operations
Other income (expense):
Interest expense, net
Early extinguishment of debt
Change in fair value of derivative liabilities
Other income, net
Income tax benefit (provision)
Total other expenses, net
Net loss
Basic and diluted net loss per share of common stock
Weighted average number of shares of common stock outstanding, basic and diluted
Statement [Table]
Statement [Line Items]
Balance
Balance, share
Exercise of stock options
Exercise of stock options, shares
Issuance of common stock upon vesting of RSUs net of tax withholding
Issuance of common stock upon vesting of RSUs net of tax withholding , shares
Sale of stock, net of offering costs (ATM)
Sale of stock, net of offering costs (ATM), shares
Exercise of warrants
Exercise of warrants, shares
The Park Acquisition
The Park Acquisition, shares
Relative fair value of warrants to purchase common stock issued in connection with note payable
Relative fair value of warrants to purchase common stock issued in connection with note payable, shares
Stock-based compensation expense
Registered public offering sale of stock, net of offering costs, March 2016
Registered public offering sale of stock, net of offering costs, March 2016, shares
Private placement, issuance of stock and warrants at $1.915 per unit, net of costs, in December 2016
Private placement, issuance of stock and warrants at $1.915 per unit, net of costs, in December 2016, shares
Stock-based payment for deferred acquisition obligation
Stock-based payment for deferred acquisition obligation, shares
Derivative liabilities in connection with convertible note and modification of warrants to purchase common stock issued in connection with note payable
Derivative liabilities in connection with convertible note and modification of warrants to purchase common stock issued in connection with note payable, shares
Net loss
Balance
Balance, share
Statement of Stockholders' Equity [Abstract]
Issuance of stock and warrants price per share
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of furniture and equipment
Amortization of intangible assets
Amortization of deferred tax liability
Amortization of debt issuance costs and discount
Debt extinguishment
Paid-in-kind interest added to principal of note payable
Non-cash gain on contingent acquisition obligations
Change in fair value of derivative liabilities
Stock-based compensation
Issuance of warrant related to litigation settlement
Changes in assets and liabilities, net of effects from acquisitions:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Deferred revenue and customer deposits
NET CASH USED IN OPERATING ACTIVITIES
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of Park Compounding, net of cash
Purchase of Central Allen Pharmacy, net of cash
Purchase of assets for ImprimisRx PA, Inc.
Payments on Pharmacy Creations contingent acquisition obligation
Investment in restricted marketable securities
Investment in patent and trademark assets
Purchases of property, plant and equipment
NET CASH USED IN INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on capital lease obligations
Net proceeds from public equity offering
Net proceeds from private placement equity offering
Payments on Park deferred acquisition obligation
Proceeds from note payable, net of issuance costs
Proceeds from convertible note payable, net of issuance costs
Proceeds from Essex leaseback, net of issuance costs
Net proceeds from ATM sales of common stock
Net proceeds (repurchases) from exercise of warrants and stock options, net of taxes remitted for RSU's
NET CASH PROVIDED BY FINANCING ACTIVITIES
NET CHANGE IN CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS, beginning of period
CASH AND CASH EQUIVALENTS, end of period
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
Cash paid for interest
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Fair value of embedded conversion feature recorded as debt discount and derivative liability
Reclassification of the fair value of the embedded conversion feature derivative liability to additional paid-in capital upon closing of the public equity offering
Reclassification of the fair value of the LSAF warrant from additional paid-in capital to derivative liability
Reclassification of the fair value of the LSAF warrant derivative liability to additional paid-in capital upon closing of the public equity offering
Reduction in value of warrant in connection with debt extinguishment
Issuance of common stock and fair value of deferred acquisition obligations related to the purchase of Park Compounding
Issuance of common stock and to settle contingent acquisition obligation related to the purchase of PC
Issuance of stock options for consulting services included in accounts payable and accrued expenses
Final fee on notes payable recorded as debt discount and included in accrued expenses
Estimated relative fair value of warrants issued in connection with note payable
Purchase of property, plant and equipment included in accounts payable and accrued expenses
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Business Combinations [Abstract]
Acquisitions
Cash and Cash Equivalents [Abstract]
Restricted Cash and Short-Term Investments
Inventory Disclosure [Abstract]
Inventories
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses
Debt Disclosure [Abstract]
Debt
Leases [Abstract]
Capital Lease Obligation
Equity [Abstract]
Stockholders' Equity (Deficit) and Stock-Based Compensation
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments
Income Tax Disclosure [Abstract]
Income Taxes
Compensation and Retirement Disclosure [Abstract]
Employee Savings Plan
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Segment Reporting [Abstract]
Segment Information and Concentrations
Subsequent Events [Abstract]
Subsequent Events
Basis of Presentation
Use of Estimates
Liquidity
Revenue Recognition and Deferred Revenue
Cost of Sales
Research and Development
Debt Issuance Costs and Debt Discount
Intellectual Property
Income Taxes
Cash and Cash Equivalents
Concentrations of Credit Risk
Accounts Receivable
Inventories
Property, Plant and Equipment
Business Combinations
Goodwill and Intangible Assets
Impairment of Long-Lived Assets
Third Party Billing and Collection Agreements
Deferred Rent
Fair Value Measurements
Derivative Instruments
Stock-Based Compensation
Basic and Diluted Net Loss per Common Share
Recently Adopted Accounting Pronouncements
Recently Issued Accounting Pronouncements
Schedule of Basic and Diluted Earnings Per Common Share
Schedule of Acquisition Date Fair Value of Consideration
Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed
Schedule of Result of Operation from Acquisition
Schedule of Intangible Assets Acquisition
Schedule of Inventories
Schedule of Prepaid Expenses and Other Current Assets
Schedule of Property, Plant and Equipment
Schedule of Intangible Assets
Schedule of Amortization Expenses for Intangible Assets
Schedule of Estimated Future Amortization Expense
Schedule of Goodwill
Schedule of Accounts Payable and Accrued Expenses
Summary of Notes Payable
Summary of Future Minimum Payments
Schedule of Future Payment Under Capital Lease
Schedule of Stock Option Plan Activity
Schedule of Market-based Vesting Conditions for Stock Option Units Granted
Schedule of Fair Value Assumption
Schedule of Shares Outstanding and Exercisable
Schedule of Market-based Vesting Conditions for Restricted Stock Units Granted
Schedule of Assumptions Used
Schedule of Restricted Stock Units Activity
Schedule of Stock Based Compensation Granted to Employees Directors Consultants
Schedule of Warrants Activity
Schedule of Warrants Outstanding and Warrants Exercisable
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Derivative Liabilities at Fair Value
Fair Value at Reconciliation of Measured Liabilities
Schedule of Provision for Income Taxes
Schedule of Income Tax Reconciliation
Schedule of Deferred Tax Assets and Liabilities
Schedule of Future Payments Under Leases
Net loss
Accumulated deficit
Net cash used in operating activities
Cash resources and restricted investments
Deposit coverage limits by FDIC, per owner
Cash deposits in excess of FDIC limits
Accounts receivable, net of allowance for doubtful accounts
Property plant and equipment useful life
Patent estimated useful life
Percentage of billing and collection amount
Billing and collection management expense
Due to related party
Anti dilutive securities
Number of shares vested during the period
Numerator - net loss
Denominator - weighted average number of shares outstanding, basic and diluted
Net loss per share, basic and diluted
Scenario [Axis]
Cash paid for business acquisition, net of fees
Payment of cash remaining in bank account
Number of common stock shares sold
Number of common stock sold
Cash payment
Issuance of common stock for payment
Issuance of common stock shares for payment
Deferred tax liability
Percentage of discount rate
Total acquisition date fair value
Deferred acquisition obligations
Acquisition adjusted description
Increase of goodwill
Increase of intangible assets
Net tangible assets
Identifiable intangible assets
Acquisition expenses
Cash payment to Sellers at closing
Restricted common stock issuance to Sellers at closing
Deferred tax liability
Deferred consideration to Sellers
Total acquisition date fair value
Cash and cash equivalents
Accounts receivable
Inventories
Furniture and equipment
Intangible assets
Total identifiable assets acquired
Accounts payable and accrued expenses
Other liabilities
Total liabilities assumed
Total identifiable assets less liabilities assumed
Net assets acquired
Total revenues
Net income
Intangible Assets Fair Value
Useful Life
Certificate of deposit
Raw materials
Finished goods
Total inventories
Prepaid insurance
Other prepaid expenses
Deposits and other current assets
Total prepaid expenses and other current assets
Depreciation and amortization of property, plant and equipment
Computer software and hardware
Furniture and equipment
Lab and pharmacy equipment
Leasehold improvements
Furniture and equipment, gross
Accumulated depreciation and amortization
Furniture and equipment, Net
Amortization periods (in years)
Amortization periods description
Cost
Accumulated amortization
Impairment
Net Carrying value
2017
2018
2019
2020
2021
Thereafter
Intangible assets
Intangible Assets And Goodwill - Schedule Of Goodwill Details
Balance beginning
Acquisition of Park (see Note 3)
Acquisition of CAP (see Note 3)
Impairment of CAP (see Note 2)
Balance ending
Accounts payable
Deferred rent
Accrued interest (see Note 10)
Accrued exit fee for note payable (see Note 10)
Building lease liability
Other accrued expenses
Total accounts payable and accrued expenses
Less: Current portion
Non-current total accrued expenses
Area of office space
Area of previous office space
Monthly rent amount
Recognized lease losses related to estimated remaining lease liability
Stock based compensation accrual
Additional paid-in-capital
Concentration Risk Benchmark [Axis]
Principal amount of loan
Loans bear interest
Loans bear interest rate description
Loan installments
Percentage of loan agreement final fee
Loan due date
Incurred expense debt
Liability of final fee included in accrued expenses
Issuance of warrants to purchase maximum number of shares
Common stock exercise price per share
Issuance of warrants to purchase of common stock expiration year
Fair value of warrants
Fair value of common stock
Fair value of contractual term
Common stock volatility rate
Fair value of dividend rate
Fair value of risk-free interest rate
Debt discount
Convertible note principal amount
Convertible note fixed per annum rate
Convertible note description
Debt conversion price per share
Proceeds from convertible note
Percentage of repurchase convertible note in cash is greater than outstanding principal amount
Fair value of embedded conversion feature
Warrants exercise price per share
December 2016 Amended Note
Less: Discounts on notes
Less: Current portion
Long-term portion
2017
2018
Total minimum payments
Less: amount representing interest
Notes payable, gross
Less: unamortized discount
Note payable, net of unamortized debt discount
Property and equipment purchase price
Lease monthly payments
Lease future payment
Lease incurred expenses
Capital lease future minimum payments percentage
Amortization of debt discount
Capital leases of equipment
Capital leases of accumulated depreciation
2017
2018
2019
Total minimum lease payments
Less: amount representing interest payments
Present value of future minimum lease payments
Present value of future net minimum lease payments
Less: current portion, net of unamortized discount
Capital lease obligation, net of current portion and unamortized discount
Consultant Tranche 1 [Axis]
Shares issued upon exercise of stock options, shares
Stock options to purchase shares of common stock
Stock option purchase of exercise price
Number of restricted stock issued
Payroll tax withholdings
Number of common stock issued for warrant exercises
Proceeds from issuance of warrants
Common stock issued upon warrants
Number of common stock isused upon cashless exercise provisions of warrants
Number of warrants issued for purchase of common stock
Percentage of cash commission
Sales commission and offering expenses
Number of shares sold under the agreement
Proceeds from sale of common stock approximately
Offerign expenses
Offering expenses description
Issuance of restricted common stock, shares
Issuance of restricted common stock
Sale of stock price per share
Proceeds from offering price
Number of shares available for sales
Number of shars issued for acquistion
Number of shars issued for acquistion, shares
Number of common stock shares issued for offering
Shares issued upon exercise of stock options
Preferred stock, shares authorized
Preferred stock, par value
Preferred stock, shares issued
Preferred stock, shares outstanding
Maximum number of common stock issuance under the plan
Intrinsic value of stock option exercised
Closing price of common stock price per share
Stock options granted with exercise price contractual terms
Stock options granted vesting terms
Average stock price targets ranging
Fair value of option
Option term
Volatility percentage
Risk free interest rate
Unrecognized compensation expense related to unvested stock options granted under the Plan
Number of restricted stock forfeit during period
Expense expected to recognize over the weighted-average remaining vesting period
Number of shares, Outstanding, Beginning balance
Number of shares, Options granted
Number of shares, Options exercised
Number of shares, Options cancelled/forfeit
Number of shares, Outstanding, Ending balance
Number of shares, Options exercisable
Number of shares, Options vested and expected to vest
Weighted Avg. Exercise Price, Outstanding, Beginning balance
Weighted Avg. Exercise Price, Options granted
Weighted Avg. Exercise Price, Options exercised
Weighted Avg. Exercise Price, Options cancelled/forfeit
Weighted Avg. Exercise Price, Outstanding, Ending balance
Weighted Avg. Exercise Price, Exercisable Ending Balance
Weighted Avg. Exercise Price, Vested and expected to vest
Weighted Avg. Remaining Contractual Life, Options outstanding
Weighted Avg. Remaining Contractual Life, Options exercisable
Weighted Avg. Remaining Contractual Life, Options vested and expected to vest
Aggregate Intrinsic Value, Options outstanding
Aggregate Intrinsic Value, Options exercisable
Aggregate Intrinsic Value, Options vested and expected to vest
Number of shares vesting
Target share price description
Weighted-average fair value of granted
Expected terms (in years)
Expected volatility
Expected volatility, minimum
Expected volatility, maximum
Risk-free interest rate
Risk-free interest rate, minimum
Risk-free interest rate, maximum
Dividend yield
Range of Exercise Prices, minimum
Range of Exercise Prices, maximum
Number of Options Outstanding
Weighted Average Remaining Contractual Life in Years
Weighted Average Exercise Price
Number Exercisable
Weighted Average Exercisable Exercise Price
Market price
Contractual terms (in years)
Expected volatility
Risk-free interest rate
Dividend yield
Number of RSUs unvested, Outstanding, Beginning balance
Number of RSUs granted
Number of RSUs vested
Number RSUs cancelled/forfeit
Number of RSUs unvested, Outstanding, Ending balance
Weighted Average Grant Date Fair Value, Beginning balance
Weighted Average Grant Date Fair Value, RSUs granted
Weighted Average Grant Date Fair Value, RSUs vested
Weighted Average Grant Date Fair Value, RSUs cancelled/forfeit
Weighted Average Grant Date Fair Value, Ending balance
Stock based compensation related to equity instruments granted to related parties
Number of shares, outstanding, beginning balance
Number of shares subject to warrants outstanding, granted
Number of shares subject to warrants outstanding, exercised
Number of shares subject to warrants outstanding, expired
Number of shares, outstanding, ending balance
Weighted average remaining contractual life of the outstanding warrants in years
Weighted avg. Exercise price, outstanding, beginning balance
Weighted avg. Exercise price, granted
Weighted avg. Exercise price, exercised
Weighted avg. Exercise price, expired/forfeited
Weighted avg. Exercise price, outstanding, ending balance
Issue Date
Warrants Outstanding
Exercise Price
Warrants Exercisable
Expiration Date
Warrants expiration date
Convertible note original maturity date
Balance Beginning
Embedded conversion feature in Convertible Note issued
Modification of warrant and reclassification from equity to liabilities
Change in fair value
Reclassification from liabilities to equity upon closing of public equity offering
Balance Ending
Income Taxes Details Narrative
Deferred tax asset valuation allowance
Federal net operating loss carryforwards
Federal net operating loss expiration date
Federal research and development tax credits
Federal research and development tax credits expiration date
State net operating loss carryforwards
State net operating loss expiration date
State research and development tax credits
Unrecognized tax benefits
Current: Federal
Current: State
Total current
Deferred: Federal
Deferred: State
Deferred: Change in valuation allowance
Total deferred
Income tax provision (benefit)
U.S. federal statutory tax rate
Benefit of lower tax brackets
State tax benefit, net
Research and development credits
Employee stock based compensation
Loss on debt conversion
Other
Valuation allowance
Effective income tax rate
NOL's
Depreciation and amortization
Other
Research & development credits
Deferred stock compensation
Park stock purchase identifiable intangibles
Unrealized gain or loss on investments
Total deferred tax assets, net
Valuation allowance
Net deferred tax liabilities
Percentage of salary deposits in tax deferred investment account
Percentage of contributions made by the company
Contributions by the company
Revenue
Number of common stock shares issued for exceeds revenue value
Fair value of divided ratio
Number of common stock shares issued for maximum exceeds from revenue
Fair value of contingent acquisition obligation
Payment of cash
Issuance of common stock to settle contingent acquisition obligation
Gain loss on contingent acquisition
Lease agreement for office space (Square feet)
Operating lease Expiry
Operating lease, monthly rental
Operating lease, rent increase percentage
Unpaid royalties
Gain on settlement
Insurance claim in other income
Accrued royalty expenses
2017
2018
2019
2020
2021
Thereafter
Total
Maximum percentage of sales derived from single customer
Percentage of drug and chemical purchases from three main suppliers
Percentage of issued and outstanding shares of common stock
Purchase consideration value
Remaining lease obligation amount
Agreement [Axis]
Andrew R Boll [Member]
Billing And Collection Agreement [Member]
Billing and collection management expense.
Building Lease Liability.
Consultant
Debt interest and interest paid in kind.
Deferred Acquisition Obligation And Accrued Interest Current.
Deferred Acquisition Obligation Noncurrent.
Deferred Acquisition Obligations, Stock Options, Unvested RSUs and Warrants [Member]
Employees [Member]
Gain on contingent acquisition obligations.
General And Administrative [Member]
Issuance Of Common Stock And Fair Value Of Deferred Acquisition Obligations Related To Purchase Of Business.
Issuance of warrants to purchase of common stock expiration year.
Lease Agreement [Member]
Lender Warrants [Member]
Life Sciences Alternative Funding LLC [Member]
Loan Agreement [Member]
Maximum deposit coverage limits.
Minimum Revenue Or Cash Balance [Member]
Non Competition Clause [Member]
Non Employee Director [Member]
Options granted to employees
Options granted to consultants
Percentage of billing and collection amount.
Percentage of cash commission.
Percentage of drug and chemical purchases from three main suppliers.
Percentage of loan agreement final fee.
Pharmacy Creations Llc [Member].
Previous office space area.
Purchase of furniture and equipment included in accounts payable and accrued expenses.
Range five [member]
Range four [member].
Range one [member].
Range three [member].
Range two [member].
Reclassification of the fair value of the embedded conversion feature derivative liability to additional paid-in capital upon closing of the public equity offering.
Recognized lease losses related to estimated remaining lease liability.
Sales Agreement [Member]
Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block].
Schedule of warrants outstanding and exercisable [Table Text Block]
Selling And Marketing [Member]
Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price.
Share based compensation arrangements by share based payment award non options expirations in period weighted average exercise price.
Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.
Share Based Compensation Award Tranche Five [Member]
Share Based Compensation Award Tranche Four [Member]
Warrants exercisable.
Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.
StockOptionPlanMember
Summary of Future Minimum Payments [Table Text Block].
Third Party Billing And Collection Agreements [Policy Text Block]
Third Party [Member]
2007 Incentive Stock and Awards Plan [Member]
Underwriter Warrants [Member].
Underwriting Agreement [Member]
Urigen Pharmaceuticals Inc [Member]
Warrants expiration date.
Warrants issuance date.
Warrants Issued To Investor Relations Consultant One [Member]
Note Purchase Agreement [Member]
8.00% Convertible Senior Secured Note [Member]
Lender [Member]
Senior Note - 2015 [Member]
Convertible Senior Note - 2016 [Member]
Warrant Derivative Liability [Member]
Embedded Conversion Feature Derivative Liability [Member]
Fair value liabilities measured on recurring basis unobservable input reconciliation reclassification from liabilities to equity upon closing of public equity offering.
Fair value liabilities measured on recurring basis unobservable input reconciliation modification of warrant and reclassification from equity to liabilities.
Fair value liabilities measured on recurring basis unobservable inputeconciliation embedded conversion feature in convertible note issued.
Mark L. Baum [Member]
Number of common stock shares issued for exceeds revenue value.
Number of common stock shares issued for maximum exceeds from revenue.
License Agreement [Member]
Notes Payable [Member]
Final fee on notes payable recorded as debt discount and included in accrued expenses.
Issuance of common stock to settle contingent acquisition obligation related to the purchase of PC.
Schedule of Market-based Vesting Conditions for Restricted Stock Units Granted [Table Text Block]
Target share price description.
Proceeds from Essex leaseback, net of issuance costs.
Issuance of warrant related to litigation settlement.
Finite Lived Intangible Assets Impairment.
Lease monthly payments.
Sales commission and offering expenses.
Settlement Warrants [Member]
Other [Member]
Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.
Lease future payment.
Accumulated Deficit [Member]
Issuance Of Common Stock Upon Vesting Of Rsus Net Of Tax Withholding.
Issuance Of Common Stock Upon Vesting Of Rsus Net Of Tax Withholding Shares.
Stock Issued During Period For Exercise Of Warrants.
Stock Issued During Period Shares For Exercise Of Warrants.
Relative fair value of warrants to purchase common stock issued in connection with note payable.
Relative fair value of warrants to purchase common stock issued in connection with note payable, shares.
Recently Adopted Accounting Pronouncements [Policy Text Block]
Acquisition of Pharmacy Creations [Member]
Acquisition of Park [Member]
Schedule of Result of Operation from Acquisition [Table Text Block].
Market-based Vesting Conditions for Stock Option Units Granted [Table Text Block]
Park [Member]
Sellers [Member]
Other Two Thousand FiFteen Acquisitions [Member].
Cash paid for business acquisition, net of fees.
Payment Of Cash Remaining In Bank Account.
Stock Issued During Period Value Issued For Payment.
Stock Issued During Period Shares Issued For Payment.
Percentage of discount rate.
Deferred Acquisition Obligations.
Acquisition adjusted description.
Restricted Common Stock Issuance To Related Party.
Business Combination Deferred tax liability.
Deferred Consideration To Related Party.
Lab And Pharmacy Equipment Gross.
Federal net operating loss expiration date.
Federal Research And Development Tax Credits.
Federal Research And Development Tax Credits Expiration Date.
State net operating loss expiration date.
State Research And Development Tax Credits.
Deferred Income Change In Valuation Allowance.
Effecticve Income Tax Rate Benefit Of Lower Tax Brackets.
Effective Income Tax Rate Loss On Debt Conversion.
Deferred Tax Asset Tax Credit carry Forwards Depreciation And Amortization.
Percentage of salary deposits in tax deferred investment account.
Shares of preferred stock and warrants for common stock issued.
Derivative liabilities in connection with convertible note and modification of warrants to purchase common stock issued in connection with note payable.
Derivative liabilities in connection with convertible note and modification of warrants to purchase common stock issued in connection with note payable, shares.
Reduction in value of warrant in connection with debt extinguishment.
Liquidity Disclosure [Policy Text Block]
Accelerated [Member]
Acquisition of related party goodwill.
Acquisition of related party goodwill.
Exchange Agreement [Member]
Placement Agent Warrants [Member]
PIPE Investor Warrants [Member]
Warrant One [Member]
Warrant Two [Member]
Warrant Three [Member]
PC [Member]
Securities Purchase Agreement [Member]
Investor Warrants [Member]
Agent Warrant [Member]
Stock Option One [Member]
Mark Baum [Member]
Baum Performance Option [Member]
John P Saharek [Member]
Mr. Boll [Member]
Boll Performance Equity Award [Member]
unvested RSUs [Member]
Number of common stock issued for warrant exercises.
Common stock issued upon warrants.
Number of common stock isused upon cashless exercise provisions of warrants.
Offering expenses description.
Average stock price targets ranging.
Accrued royalty expenses.
Imprimis TX [Member]
Livernois [Member]
Percentage of issued and outstanding shares of common stock.
Payment of cash.
Closing price of common stock price per share.
Amortization of income tax provision.
Unrecognized compensation expense related to unvested stock options
Assets, Current
Assets
Liabilities, Current
Liabilities
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Revenue, Net
Health Care Organization, Medical Supplies and Drugs Expense
Gross Profit
Operating Costs and Expenses
Operating Income (Loss)
Nonoperating Income (Expense)
Shares, Outstanding
StockOptionPlanMember
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Increase (Decrease) in Employee Related Liabilities
Increase (Decrease) in Customer Deposits
Net Cash Provided by (Used in) Operating Activities
Payments for Previous Acquisition
Payments to Acquire Marketable Securities
Payments to Acquire Intangible Assets
Net Cash Provided by (Used in) Investing Activities
Repayments of Debt and Capital Lease Obligations
Payments of Financing Costs
Net Cash Provided by (Used in) Financing Activities
Inventory Disclosure [Text Block]
Income Tax, Policy [Policy Text Block]
Inventory, Policy [Policy Text Block]
Property, Plant and Equipment, Policy [Policy Text Block]
Derivatives, Policy [Policy Text Block]
Deferred Tax Liabilities, Net
BusinessCombinationDeferredTaxLiability
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net
Business Combination, Separately Recognized Transactions, Net Gains and Losses
Property, Plant and Equipment, Gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Net
Accounts Payable and Accrued Liabilities
Debt Instrument, Unamortized Discount
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months
Long-term Debt, Maturities, Repayments of Principal in Year Two
Debt Instrument, Unamortized Discount (Premium), Net
Capital Leases, Future Minimum Payments Due, Next Twelve Months
Capital Leases, Future Minimum Payments Due in Two Years
Capital Leases, Future Minimum Payments Due in Three Years
Capital Leases, Future Minimum Payments Due
Capital Leases, Future Minimum Payments, Interest Included in Payments
Capital Leases, Future Minimum Payments, Net Minimum Payments
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs
Current Income Tax Expense (Benefit)
Deferred Income Tax Expense (Benefit)
Deferred Tax Assets, Tax Credit Carryforwards, Other
Deferred Tax Assets, Net of Valuation Allowance
Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Net
Operating Leases, Future Minimum Payments, Next Rolling Twelve Months
Operating Leases, Future Minimum Payments, Due in Rolling Year Two
Operating Leases, Future Minimum Payments, Due in Rolling Year Three
Operating Leases, Future Minimum Payments, Due in Rolling Year Four
Operating Leases, Future Minimum Payments, Due in Rolling Year Five
Operating Leases, Future Minimum Payments, Due in Rolling after Year Five
Operating Leases, Future Minimum Payments Due